|
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Whole-Genome Sequencing Coupled to Imputation Discovers Genetic Signals for Anthropometric Traits.
|
28552196 |
2017 |
|
Esophageal Neoplasms
|
0.100 |
GeneticVariation
|
group |
GWASDB |
Genome-wide association analyses of esophageal squamous cell carcinoma in Chinese identify multiple susceptibility loci and gene-environment interactions.
|
22960999 |
2012 |
|
Hair Color
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genome-wide study of hair colour in UK Biobank explains most of the SNP heritability.
|
30531825 |
2018 |
|
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
Cell viability, cell proliferation, and invasion of HCC827 cells in the PEBP4 knockdown group were significantly lower than that in the negative control and blank control groups (p < 0.05), and there were no significant differences between the negative and blank control groups in terms of cell viability, cell proliferation, apoptosis, and invasion.
|
22983920 |
2013 |
|
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
Whereas knockdown of PEBP4 suppressed NSCLC cell migration, PEBP4, and invasion with prevented EMT.
|
30367510 |
2019 |
|
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
In addition, it was demonstrated that PEBP4 was associated with the development and invasion of gastric cancer cells through activation of the PI3K/Akt signaling pathway.
|
28193908 |
2017 |
|
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
Furthermore, knockdown of PEBP4 suppressed breast cancer cell migration and invasion with prevented EMT.
|
28415045 |
2017 |
|
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Role of the PEBP4 protein in the development and metastasis of gastric cancer.
|
28193908 |
2017 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Knockdown of PEBP4 inhibited breast cancer cell proliferation in vitro and tumor growth in vivo.
|
28415045 |
2017 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
These data indicate a clinical significance of PEBP4 for predicting the tumor grade and the prognosis in patients with gliomas.
|
26725095 |
2016 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
The Roles And Signaling Pathways Of Phosphatidylethanolamine-Binding Protein 4 In Tumors.
|
31571919 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Whereas knockdown of PEBP4 suppressed NSCLC cell migration, PEBP4, and invasion with prevented EMT.
|
30367510 |
2019 |
|
Carcinogenesis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
In conclusion, the present study demonstrated for the first time that knockdown of PEBP4 inhibited the proliferation, invasion and tumorigenesis in breast cancer cells.
|
28415045 |
2017 |
|
Carcinogenesis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Together, these results suggest that PEBP4 may promote tumorigenesis in NSCLC by regulating cell proliferation and EMT via activation of the Shh signaling pathway.
|
30367510 |
2019 |
|
Malignant neoplasm of breast
|
0.020 |
Biomarker
|
disease |
BEFREE |
Silencing of human phosphatidylethanolamine-binding protein 4 sensitizes breast cancer cells to tumor necrosis factor-alpha-induced apoptosis and cell growth arrest.
|
16243830 |
2005 |
|
Malignant neoplasm of breast
|
0.020 |
Biomarker
|
disease |
BEFREE |
Thus, PEBP4 may serve as a potential therapeutic target for the treatment of breast cancer.
|
28415045 |
2017 |
|
Tumor Progression
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Phosphatidylethanolamine-binding protein 4 (PEBP4), a member of the PEBP family, plays a pivotal role in tumor progression.
|
28415045 |
2017 |
|
Tumor Progression
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Phosphatidylethanolamine-binding protein 4 (PEBP4), a member of the PEBP family, has been reported to play a pivotal role in tumor progression.
|
30367510 |
2019 |
|
Breast Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Silencing of human phosphatidylethanolamine-binding protein 4 sensitizes breast cancer cells to tumor necrosis factor-alpha-induced apoptosis and cell growth arrest.
|
16243830 |
2005 |
|
Breast Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Thus, PEBP4 may serve as a potential therapeutic target for the treatment of breast cancer.
|
28415045 |
2017 |
|
Glioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
By stable lentiviral vector-mediated silencing of PEBP4, we examined the effects of PEBP4 knockdown on the growth, apoptosis, and invasion of U251 and U373 human glioma cell lines using MTT, Transwell, colony formation, and flow cytometric assays.
|
30255656 |
2019 |
|
IGA Glomerulonephritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
The function of PEBP4 in IgAN or renal disease is unknown.
|
31402200 |
2019 |
|
Lung Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Pretreatment with pcDNA3.1-PEBP4 promoted the proliferation, invasion, and migration of NSCLC cells and increased EMT in vitro and lung tumor metastasis in vivo.
|
30367510 |
2019 |
|
Malignant neoplasm of stomach
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our findings supported the hypothesis that PEBP4 might be a novel potential drug target for the treatment of gastric cancer.
|
28193908 |
2017 |
|
B-Cell Lymphomas
|
0.010 |
Biomarker
|
group |
BEFREE |
Silencing of human phosphatidylethanolamine-binding protein 4 enhances rituximab-induced death and chemosensitization in B-cell lymphoma.
|
23451095 |
2013 |